linjc16/ctgov huggingface dataset:
Bleeding Prediction in Thrombocytopenia

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to investigate whether platelet indices from automated haematology equipment, whole blood impedance aggregometry and a standardized bleeding questionnaire predict bleeding in admitted patients with thrombocytopenia of various causes.

Detailed Description
-----------------
Thrombocytopenia is a risk factor for bleeding, but studies concerning markers for stratification of bleeding risk among thrombocytopenic patients are lacking. This prospective observational cohort study investigates risk factor for bleeding in admitted patients with thrombocytopenia of various causes.

Official Title
-----------------
Bleeding Prediction in Thrombocytopenia Using Platelet Indices, Platelet Aggregometry and a Standardized Bleeding Questionnaire

Conditions
-----------------
Thrombocytopenia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Admitted patients with thrombocytopenia Age ≥18 years Platelet count below 80 x109/L Exclusion Criteria: Platelet transfusion within the previous 14 days, surgery or trauma within the previous 7 days Unable to give informed consent.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean platelet volume | Mean platelet volume (femtolitre (fL)) | 30 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Platelet count | Platelet count ( x10'9/L) | 30 days | 
| immature platelet fraction | immature platelet fraction (%) | 30 days | 
| Bleeding questionnaire | Bleeding score based on the condensed MCMDM-1 VWD bleeding questionnaire | 30 days | 
| Platelet aggregation | Platelet aggregation by Multiplate Analyzer (aggregation units* min) | 30 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Bleeding, Platelet indices, Platelet aggregometry, Bleeding questionnaire
Post-authorization Safety Study of Euforvac-Hib Vaccine for Active Primary Immunization in Infants From 6 Weeks

Study Overview
=================
Brief Summary
-----------------
A multicenter, observational study to evaluate the safety of Euforvac-Hib vaccine for active primary immunization against diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenza type B in infants.

Detailed Description
-----------------
Euforvac-Hib vaccine manufactured by LG Life science in Korea, but it's not marketed in Korea. It is distributed to UN agencies in diverse countries. Thus, WHO recommended LG Life Science to conduct the safety study for assessing the vaccine safety if Euforvac-Hib is prequalified. The objectives of this safety study are to identify any problems and questionable issues likely to emerge from the actual use of Euforvac-Hib vaccine after launching in the market.

Official Title
-----------------
A Multicenter, Post-authorization Safety Study of Euforvac-Hib Vaccine for Active Primary Immunization Against Diphtheria, Tetanus, Pertussis, Hepatitis B and Haemophilus Influenza Type B in Infants

Conditions
-----------------
Diphtheria, Tetanus, Pertussis, Hepatitis B, Haemophilus Influenza Type B

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who had been signed informed consent by subjects legally acceptable Representative Infant from 6 weeks of age.who is given this vaccine for active primary immunization against diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenza type B Exclusion Criteria: Patients with hypersensitivity to any component for the vaccine Patients who had a severe reaction to a previous dose of the combination vaccine or any of its constituents is absolute contraindication to subsequent doses of the combination vaccine. Patients who had pertussis, encephalopathy or other serious neurological abnormality in the newborn period

Ages Eligible for Study
-----------------
Minimum Age: 6 Weeks

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Euforvac-Hib vaccine<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse event |  | up to 12 weeks after vaccination |
Promotion of Healthy Lifestyle Habits in a Primary Care Setting

Study Overview
=================
Brief Summary
-----------------
Intervention aiming to promote healthy dietary and physical activity behaviors in adults with low socio-economic position in a primary health care setting

Official Title
-----------------
Promotion of Healthy Lifestyle Habits in a Primary Care Setting

Conditions
-----------------
Healthy Lifestyle

Intervention / Treatment
-----------------
* Behavioral: Healthy lifestyle


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age, high metabolic risk- poor lifestyle habits (diet and physical activity) Exclusion Criteria: overt disease

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: intervention<br> | Behavioral: Healthy lifestyle<br>* Promotion of healthy lifestyle behaviors<br>|
| No Intervention: Control<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in blood glucose | Blood glucose (mmol/L) assessed using chemistry kits from Ortho-Clinical Diagnostics on a Vitros-5.1 analyzer platform (Clinical Diagnostics, Raritan, NJ, United States) | Before ; at 16 weeks; at 24 months | 
| Change in plasma triglycerides | Plasma triglycerides (mmol/L) : assessed using chemistry kits from Ortho-Clinical Diagnostics on a Vitros-5.1 analyzer platform (Clinical Diagnostics, Raritan, NJ, United States) | Before ; at 16 weeks; at 24 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in waist circumference | waist circumference (cm) assessed by a steel tape | Before ; at 16 weeks; at 24 months |
Phase II Pilot Study of Extracorporeal Phototherapy for Epidermolysis Bullosa Acquisita

Study Overview
=================
Brief Summary
-----------------
OBJECTIVES: I. Evaluate immunomodulation with extracorporeal photochemotherapy (ECP) in patients with epidermolysis bullosa acquisita. II. Investigate the effect of ECP on lymphocyte activity.

Detailed Description
-----------------
PROTOCOL OUTLINE: Oral methoxsalen (8-MOP) is administered 90 minutes prior to leukapheresis. Blood mononuclear cells are exposed to ultraviolet A light for 3 hours, then returned to the patient. The process is repeated on 2 successive days. Patients are re-treated every 3 to 4 weeks for a total of 6 treatments or until the skin has cleared.

Conditions
-----------------
Epidermolysis Bullosa Acquisita

Intervention / Treatment
-----------------
* Drug: methoxsalen


Participation Criteria
=================
Eligibility Criteria
-----------------
Active epidermolysis bullosa acquisita

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: methoxsalen|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
dermatologic disorders, epidermolysis bullosa, genetic diseases and dysmorphic syndromes, rare disease
Comparison of Different Feature Engineering Methods for Automated ICD Coding

Study Overview
=================
Brief Summary
-----------------
Using traditional machine learning classifiers, this study targets on comparing bag-of-words, word2cec and roberta on automated ICD coding related to cardiovascular diseases in Chinese corpus.

Detailed Description
-----------------
ICD coding is quite important as it serves as basis for a wide range of economic and academic applications. Currently, manual coding is mainly adopted, which faces several limits like being time-consuming and prone to error, and this makes automated ICD coding via machine learning a hot research topic. As an inevitable phase during machine learning, feature engineering plays a crucially important role in leading to promising coding performance. Although have reached enlightening conclusions, existing studies lacked comparison of different feature engineering methods. Finding out what methods under what circumstances perform better can be quite helpful in promoting practical applications of automated coding. The investigators will implement this study based on inpatient' data collected from electronic medical records from Fuwai Hospital, the world's largest medical center for cardiovascular disease. Bag-of-words, word2cec and roberta will be respectively used to extracted features from training data. Then code-wise logistic regression classifiers and support vector machine classifiers will be trained to auto-assign codes. Afterwards, performances of the models on test data will be evaluated.

Official Title
-----------------
Comparison of Different Feature Engineering Methods for Automated ICD Coding

Conditions
-----------------
Cardiovascular Diseases

Intervention / Treatment
-----------------
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Admissions in Fuwai Hospital, from January 1, 2019, to February 28, 2019 Exclusion Criteria: -
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Model training and test group<br>Data set will be split into training group and test group, where training group will be used for model building, and test group for subsequent evaluation and verification. | Other: No intervention<br>* No intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ICD-10 codes for each admission | Each admission will be a sample in this study. The ICD-10 codes assigned by medical coders for each admission will be collected as the primary outcome. | At the end of enrollment |
Uniform Communication by Midwives in Preparation for an IVF Treatment

Study Overview
=================
Brief Summary
-----------------
Dutch-speaking women who are about to start an IVF treatment will be approached. If they are willing to participate in the study, they will receive an email with a link to an online questionnaire. This questionnaire will evaluate the communication by the midwive in preparation for an IVF treatment. When 50 women have completed the questionnaire a standardized communication protocol will be enrolled. Once all midwives are trained, 50 other IVF patients will be asked to complete the slightly adapted post questionnaire.The data from both questionnaires will be compared.

Official Title
-----------------
Uniform Communication by Midwives in Preparation for an IVF Treatment

Conditions
-----------------
IVF, Communication

Intervention / Treatment
-----------------
* Other: Questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: women who are about to start an IVF treatment at our department Exclusion Criteria: non-Dutch speaking women who are counseled by one of the midwives involved in the design of this study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| PRE implementation communication protocol<br> | Other: Questionnaire<br>* A digital questionnaire to evaluate the communication by midwives will be send out to IVF patients<br>|
| POST implementation communication protocol<br> | Other: Questionnaire<br>* A digital questionnaire to evaluate the communication by midwives will be send out to IVF patients<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| How do patients evaluate the communication by the midwife in anticipation of the IVF treatment cycle? | Self created questionnaire (no scale) | About 20 weeks counting from the launch of each questionnaire or earlier if the target of 50 patients is reached sooner |
Microvesicle Production After Acute Trauma and Its Clinical Impact on Venothromboembolism

Study Overview
=================
Brief Summary
-----------------
The purpose of this research study is to look at how trauma affects the ability of blood to clot. The blood of people who suffer a traumatic injury can under-clot or over-clot, and this research study will look at blood drawn from people after they suffer a traumatic injury to see how well their blood clots.

Official Title
-----------------
Microvesicle Production After Acute Trauma and Its Clinical Impact on Venothromboembolism

Conditions
-----------------
Venothromboembolism

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male and female patients 18 years of age or older Blunt trauma patients including those with closed head injury Penetrating trauma patients Exclusion Criteria: Are on therapeutic anticoagulation Have preexisting coagulopathy Patients greater than 12 hours from time of injury Have history of malignancy or preexisting diagnosis of sepsis or renal failure Patients with burn injuries Male and female patients younger than 18 years of age Pregnant patients

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Traumatic Injury<br>Trauma patients arriving at Saint Mary's Emergency Department | |
| Control group<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Estimate the distribution over time of procoagulant Microvesicles (MVs) concentration by cell of origin and endogenous thrombin potential (ETP). |  | 6 months | 
| Determine the cumulative incidence of Venothromboembolism (VTE) within three months after major trauma and test the distribution of procoagulant MV concentration and endogenous thrombin generation potential over time as potential predictors of VTE. |  | 4 years |
Effect of Diacylglycerol Oil on Risk Factors of Type 2 Diabetes and Complicating Disease, and Mechanism

Study Overview
=================
Brief Summary
-----------------
Diacylglycerol oil has been shown to lower postprandial and fasting serum triacylglycerol levels and reduce body fat. The investigators hypothesize that replacing dietary fat with diacylglycerol oil reduces excess body fat in type 2 diabetic patients and that diacylglycerol oil has a beneficial effect on cardiovascular risk factors in Chinese type 2 diabetic patients.

Official Title
-----------------
Effect of Diacylglycerol Oil on Risk Factors of Type 2 Diabetes and Complicating Disease, and Mechanism

Conditions
-----------------
Insulin Sensitivity, Type 2 Diabetes, Cardiovascular Disease

Intervention / Treatment
-----------------
* Dietary Supplement: diacylglycerol oil
* Dietary Supplement: triacylglycerol oil


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Type 2 diabetic patients, blood sugar levels were stabilized between 7.0-10.0 mmol/L Male, aged 40 - 70 years old, Female, aged post-menopausal - 70 years old. Overweight/obese patients (BMI 25 - 40 kg/m2) Currently under diet therapy for diabetes mellitus Understands the procedures and willing to participate in the study Exclusion Criteria: Patients who unwilling to give informed consent Type 1 diabetic patients Familial hyperlipemia patients or blood triacylglycerol concentration > 400 mg/dl Patients with a history of cardiovascular disease and/or arteriosclerotic disease Patients with a history of cerebrovascular disease Patients with serious hepatic disease and/or renal disease Patients with malignancy Participation in another clinical study within 30 days prior to screening period. Has a condition the doctor in charge believes would interfere with evaluation of the subject, or may put subject at undue risk

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: DAG oil<br> | Dietary Supplement: diacylglycerol oil<br> <br> |
| Placebo Comparator: TAG oil<br> | Dietary Supplement: triacylglycerol oil<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| insulin resistance |  | 120 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
diacylglycerol oil, insulin sensitivity, type 2 diabetes, cardiovascular disease, risk factors
Clinical Audit On Management Of Congenital Heart Disease In ACUH

Study Overview
=================
Brief Summary
-----------------
Congenital Heart Disease (CHD) is the most common birth defect in the United States, affecting approximately 0.8% of live births. Improved treatment strategies and interventions have increased survival such that 85% to 90% of affected children are expected to live well into adulthood, thereby causing a demographic shift in which adults now outnumber children with CHD, and more people with complex CHD are living longer.

Detailed Description
-----------------
CHD may be defined as an anatomic malformation of the heart or great vessels which occurs during intrauterine development, irrespective of the age at presentation. The cause of most congenital heart defects is still unknown. Many cases of congenital heart disease are multifactorial and result from a combination of genetic predisposition and an environmental stimulus. A small percentage of congenital heart lesions are related to known chromosomal abnormalities, in particular, trisomy 21, 13, and 18 and Turner syndrome. Of all cases of congenital heart disease, 2-4% are associated with known environmental or adverse maternal conditions and teratogenic influences, including maternal diabetes mellitus, phenylketonuria, systemic lupus erythematosus or congenital rubella syndrome; and maternal ingestion of drugs (lithium, ethanol, warfarin, antimetabolites, vitamin A derivatives, anticonvulsant agents).

Official Title
-----------------
Clinical Audit On Management Of Congenital Heart Disease In Assiut Children University Hospital

Conditions
-----------------
Congenital Heart Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: children with CHD more than one month Exclusion Criteria: children with CHD less than one month

Ages Eligible for Study
-----------------
Minimum Age: 1 Month
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical audit study to assess management of congenital heart disease in AUCH | To assess how much the adopted protocol of management of congenital heart disease is implemented in Assiut university children hospital | One year |
To Explore the Influence of Appetite Reduction and Medication Effect of Methylphenidate in Patients With Attention-deficit/Hyperactivity Disorder(ADHD) Through Pharmacogenetics.

Study Overview
=================
Brief Summary
-----------------
We plan to recruit 200 children and adolescents aged between 6 to 17 years old in two years. Those patients would receive clinical interview by child psychiatrists to diagnose as ADHD and to exclude mental retardation, major psychiatric disorders and medical disorders. Moreover, we excluded children who ever received ADHD medication treatment more than one year, or received medication in recent 30 days. Initial assessment includes collecting saliva sample, and complete questionnaires (SNAP-IV), clinical rating (CGI-S) and psychological test (CPT-II, WISC-IV, CANTAB). After 1 month methylphenidate treatment, we would evaluate SNAP-IV, CGI-S, CGI-I and Barkley Psychostimulants Side Effects Rating Scale. We also would collect saliva samples to perform appetite related gene phenotyping to see the association between medication side effect and polymorphism of appetite related genes.

Official Title
-----------------
To Explore the Influence of Appetite Reduction and Medication Effect of Methylphenidate in Patients With Attention-deficit/Hyperactivity Disorder Through Pharmacogenetics.

Conditions
-----------------
Methylphenidate Adverse Reaction

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age range from 6 years old to17 years old Diagnosis of ADHD. Exclusion Criteria: mental retardation. major psychiatric disorders major medical disorders.

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Barkley psychostimulants side effect scale | This scale included 17 most common side-effects of methylphenidate. The occurrence of each side-effect was rated on a Likert scale ranging from 0 (not a problem) to 9 (severe). | One month methylphenidate use | 
| Clinical Global Impression scale-Improvement (CGI-I) | This scale was used to evaluate the improvement after medication treatment. It's a Likert scale range from 1 (very much improved) through to 7 (very much worse). | One month methylphenidate use |